Head to head

Elite iQ vs Motus AX (2026)

Compare purchase costs, running costs and the evidence behind each device.

Read the comparison overview

Purchase cost: The catalog lists $85k–$115k for Elite iQ. No new-price range is on file for Motus AX. Check the source notes and request current quotes.
Practice fit: Elite iQ: dual-wavelength platform. Motus AX: alexandrite laser (in-motion). Check each model’s US regulatory status and labeled indications for your intended use.

Device A

Dual-wavelength platform

View full device profile →

Device B

Alexandrite laser (in-motion)

View full device profile →

Price comparison

Price comparison: Cynosure Elite iQ vs DEKA Motus AX
Attribute	Cynosure Elite iQ	DEKA Motus AX
New price range	$85k–$115kSource not documented	Not published
Used asking range	$45k–$70kSource not documented	$45k–$70kSource not documented
Payback calculator	View ROI calculator	View ROI calculator
Next step		Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models. Browse current models

New price range

Cynosure Elite iQ: $85k–$115kSource not documented
DEKA Motus AX: Not published

Used asking range

Cynosure Elite iQ: $45k–$70kSource not documented
DEKA Motus AX: $45k–$70kSource not documented

Payback calculator

Cynosure Elite iQ: View ROI calculator
DEKA Motus AX: View ROI calculator

Next step

Cynosure Elite iQ

DEKA Motus AX

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

Consumable economics

Consumable economics: Cynosure Elite iQ vs DEKA Motus AX
Attribute	Cynosure Elite iQ	DEKA Motus AX
Consumable cost / lock-in	Supply pricing is not documented with a dated source yet. Request an itemized supply quote.	—
Service cost	Not published	Not published

Consumable cost / lock-in

Cynosure Elite iQ: Supply pricing is not documented with a dated source yet. Request an itemized supply quote.
DEKA Motus AX: —

Service cost

Cynosure Elite iQ: Not published
DEKA Motus AX: Not published

FDA clearance

FDA clearance: Cynosure Elite iQ vs DEKA Motus AX
Attribute	Cynosure Elite iQ	DEKA Motus AX
FDA status & indication	FDA ClearedK193426, K240396 Read FDA indication wording “755nm: The Elite iQ laser is indicated for stable long-term or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowing when measured at 6, 9 or 12 months after the completion of a treatment regime. It is used for skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles. 1064nm: The Elite iQ laser is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, venous lakes, leg veins, spider veins and poikiloderma of Civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigines (age spots), solar lentigines (sunspots), cafe au lait macules, seborrheic keratoses, nevi, chloasma, 755 nm: The Cynosure Elite+ Laser is indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowting when measured 6, 9, or 12 months after the completion of a treatment regime. It is used for all skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles. 1064 nm: The Cynosure Elite+ Laser is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic 755mn laser: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime. On all skin types (Fitzpatrick I - VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles.”	FDA ClearedK181486, K211821 Read FDA indication wording “Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB . The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

FDA status & indication

Cynosure Elite iQ: FDA ClearedK193426, K240396
Read FDA indication wording
“755nm: The Elite iQ laser is indicated for stable long-term or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowing when measured at 6, 9 or 12 months after the completion of a treatment regime. It is used for skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles. 1064nm: The Elite iQ laser is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangiectasia, rosacea, venous lakes, leg veins, spider veins and poikiloderma of Civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigines (age spots), solar lentigines (sunspots), cafe au lait macules, seborrheic keratoses, nevi, chloasma, 755 nm: The Cynosure Elite+ Laser is indicated for stable long-term, or permanent hair reduction. Permanent hair reduction is defined as long-term stable reduction in the number of hairs regrowting when measured 6, 9, or 12 months after the completion of a treatment regime. It is used for all skin types (Fitzpatrick I-VI) including tanned skin. It is also indicated for the treatment of vascular lesions, benign pigmented lesions, and wrinkles. 1064 nm: The Cynosure Elite+ Laser is intended for the coagulation and hemostasis of benign vascular lesions such as, but not limited to, port wine stains, hemangiomas, warts, telangectasia, rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic 755mn laser: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime. On all skin types (Fitzpatrick I - VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles.”
DEKA Motus AX: FDA ClearedK181486, K211821
Read FDA indication wording
“Alexandrite 755nm laser source: Temporary hair reduction. Stable long-term or permanent hair reduction through selective targeting of melanin in hair follicles. Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6,9, and 12 months after the completion of a treatment regime, on all skin types (Fitzpatrick I – VI) including tanned skin. Treatment of benign pigmented lesions. Treatment of wrinkles. Photocoagulation of benign dermatological vascular lesions (such as port-wine stains, hemangiomas, telangiectasias). Nd:YAG 1064nm laser source: Removal of unwanted hair, for stable long term or permanent hair reduction and for treatment of PFB . The lasers are indicated on all Skin Types Fitzpatrick I-VI including tanned skin. Photocoagulation and hemostasis of benign pigmented and benign vascular lesions, such as but not limited to port wine stains, hemangioma, warts, teleangiectasia, rosacea, venus lake, leg veins and spider veins. Coagulation and hemostasis of soft tissue. Benign pigmented lesions such as, but not limited to, lentigos, (age spots), solar lentigos (sun spots), cafe au lait macules, seborrheic keratosis, nevi, cloasma, verrucae, skin tags, keratosis and plaques. The laser is indicated for benign pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The laser is also indicated for the reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Treatment of wrinkles.”

Which chains run each

Which chains run each: Cynosure Elite iQ vs DEKA Motus AX
Attribute	Cynosure Elite iQ	DEKA Motus AX
Chain adoption	2 recorded pairings	0 recorded pairings
Chains using it	SEV Laser(Confirmed) Foxy Box Laser + Wax Bar(Confirmed)	—
Approved reviews	0	0

Chain adoption

Cynosure Elite iQ: 2 recorded pairings
DEKA Motus AX: 0 recorded pairings

Chains using it

Cynosure Elite iQ: SEV Laser(Confirmed)
Foxy Box Laser + Wax Bar(Confirmed)
DEKA Motus AX: —

Approved reviews

Cynosure Elite iQ: 0
DEKA Motus AX: 0

Specs and platform

Specs and platform: Cynosure Elite iQ vs DEKA Motus AX
Attribute	Cynosure Elite iQ	DEKA Motus AX
Manufacturer	Cynosure	DEKA
Built by (OEM)	Cynosure LLC	DEKA M.E.L.A. S.r.l.
Category	Dual-wavelength platform	Alexandrite laser (in-motion)
Technology	755/1064nm + Skintel melanin reader (Alexandrite)	755nm Moveo alexandrite (Alexandrite)
Launch year	2020	2018
Status	Current	Discontinued
Manufacturer source record	No linked source on file.	No linked source on file.

Manufacturer

Cynosure Elite iQ: Cynosure
DEKA Motus AX: DEKA

Built by (OEM)

Cynosure Elite iQ: Cynosure LLC
DEKA Motus AX: DEKA M.E.L.A. S.r.l.

Current alternatives

Current catalog models in related categories. Confirm availability and configuration with the supplier.

DEKA Motus PRO

Alexandrite laser (in-motion)

New: —

Get a free recommendation Browse by goal

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.